News AbbVie bags first approval for cancer ADC Emrelis AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
News AbbVie makes its tariffs-driven investment play AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.
News AbbVie files fast-acting Botox successor in US AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.
News Rinvoq cleared for giant cell arteritis in EU, ahead of US AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis.
News AbbVie sues Genmab, claiming trade secrets theft A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets.
News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
